(Q24246391)

https://api.crossref.org/works/10.1002%2F14651858.CD003370.PUB2

Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003370.PUB2

Advanced breast cancer updates on anastrozole versus tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003370.PUB2

Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003370.PUB2

Efficacy of tamoxifen following anastrozole ('Arimidex') compared with anastrozole following tamoxifen as first-line treatment for advanced breast cancer in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003370.PUB2

Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003370.PUB2

Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003370.PUB2

Randomized trial comparing aminoglutethimide with high-dose medroxyprogesterone acetate in therapy for advanced breast carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003370.PUB2

Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Letrozole International Trial Group (AR/BC3).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003370.PUB2

Cost-effectiveness analysis of exemestane compared with megestrol in patients with advanced breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003370.PUB2

Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003370.PUB2

A randomized, open, parallel-group trial to compare the endocrine effects of oral anastrozole (Arimidex) with intramuscular formestane in postmenopausal women with advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003370.PUB2

Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003370.PUB2

Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003370.PUB2

Fulvestrant (Faslodex) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003370.PUB2

Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003370.PUB2

Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003370.PUB2

Fulvestrant versus anastrozole as second-line treatment of advanced breast cancer in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003370.PUB2

Superiority of letrozole to tamoxifen in the first-line treatment of advanced breast cancer: evidence from metastatic subgroups and a test of functional ability

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003370.PUB2

Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003370.PUB2

Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003370.PUB2

The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: a companion study to EORTC Trial 10951, 'Randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane o

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003370.PUB2

Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003370.PUB2

An open randomised trial of second-line endocrine therapy in advanced breast cancer. comparison of the aromatase inhibitors letrozole and anastrozole

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003370.PUB2

An open randomised trial of second-line endocrine therapy in advanced breast cancer: comparison of the Aromatase inhibitors letrozole and anastrozole

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003370.PUB2

Megestrol acetate and aminoglutethimide/hydrocortisone in sequence or in combination as second-line endocrine therapy of estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003370.PUB2

Defining clinical benefit in postmenopausal patients with breast cancer under second-line endocrine treatment: does quality of life matter?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003370.PUB2

Double-blind randomised trial comparing the non-steroidal aromatase inhibitors letrozole and fadrozole in postmenopausal women with advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003370.PUB2

Endocrinological and clinical evaluation of two doses of formestane in advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003370.PUB2

The minimal effective exemestane dose for endocrine activity in advanced breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003370.PUB2

Potency and selectivity of the non-steroidal aromatase inhibitor CGS 16949A in postmenopausal breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003370.PUB2

Therapeutic effects of the aromatase inhibitor fadrozole hydrochloride in advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003370.PUB2

Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003370.PUB2

Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003370.PUB2

A study of fadrozole, a new aromatase inhibitor, in postmenopausal women with advanced metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003370.PUB2

Recent advances in endocrine therapy of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003370.PUB2

A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003370.PUB2

Use of aromatase inhibitors in postmenopausal women with advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003370.PUB2

Double-blind, randomised, multicentre endocrine trial comparing two letrozole doses, in postmenopausal breast cancer patients1Accepted as a poster presentation to the 34th Annual Meeting of the American Society of Clinical Oncology, May 1998, Los Ang

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003370.PUB2

Cost-effectiveness implications of increased survival with anastrozole in the treatment of advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003370.PUB2

Static disease on anastrozole provides similar benefit as objective response in patients with advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003370.PUB2

Assessment of response to therapy in advanced breast cancer: a project of the Programme on Clinical Oncology of the International Union Against Cancer, Geneva, Switzerland

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003370.PUB2

7 January 2021

Fadrozole HCL (CGS-16949A) versus megestrol acetate treatment of postmenopausal patients with metastatic breast carcinoma: results of two randomized double blind controlled multiinstitutional trials

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003370.PUB2

7 January 2021

Fadrozole hydrochloride in postmenopausal patients with metastatic breast carcinoma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003370.PUB2

7 January 2021

A randomized phase II trial of two dosage levels of letrozole as third-line hormonal therapy for women with metastatic breast carcinoma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003370.PUB2

7 January 2021

Effect of two 4-hydroxyandrostenedione doses on serum insulin-like growth factor I levels in advanced breast cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003370.PUB2

7 January 2021

Low dose aminoglutethimide without hydrocortisone for the treatment of advanced postmenopausal breast cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003370.PUB2

7 January 2021

Endocrine changes with the aromatase inhibitor fadrozole hydrochloride in breast cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003370.PUB2

7 January 2021

Sex hormone levels in postmenopausal women with advanced metastatic breast cancer treated with CGS 169 49A

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003370.PUB2

7 January 2021

Second line endocrine treatment of postmenopausal advanced breast cancer. Preliminary endocrine results of a 5-arm randomized phase II trial of medium vs low dose aminoglutethimide, with or without hydrocortisone vs hydrocortisone alone (EORTC 10861

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003370.PUB2

7 January 2021

Fadrozole hydrochloride, a new nontoxic aromatase inhibitor for the treatment of patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003370.PUB2

7 January 2021

Treatment of disseminated breast cancer with tamoxifen, aminoglutethimide, hydrocortisone, and danazol, used in combination or sequentially

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003370.PUB2

7 January 2021

Formestane versus megestrol acetate in postmenopausal breast cancer patients after failure of tamoxifen: a phase III prospective randomised cross over trial of second-line hormonal treatment (SAKK 20/90). Swiss Group for Clinical Cancer Research (SA

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003370.PUB2

7 January 2021

Quality of life in postmenopausal patients with breast cancer after failure of tamoxifen: formestane versus megestrol acetate as second-line hormonal treatment. Swiss Group for Clinical Cancer Research (SAKK)

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003370.PUB2

7 January 2021

The aromatase inhibitor letrozole in advanced breast cancer: Effects on serum insulin-like growth factor (IGF)-I and IGF-binding protein-3 levels

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003370.PUB2

7 January 2021

Combined endocrine treatment of elderly postmenopausal patients with metastatic breast cancer. A randomized trial of tamoxifen vs. tamoxifen + aminoglutethimide and hydrocortisone and tamoxifen + fluoxymesterone in women above 65 years of age

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003370.PUB2

7 January 2021

A randomised study of CGS 16949A (fadrozole) versus tamoxifen in previously untreated postmenopausal patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003370.PUB2

7 January 2021

First-line fadrozole HCI (CGS 16949A) versus tamoxifen in postmenopausal women with advanced breast cancer. Prospective randomised trial of the Swiss Group for Clinical Cancer Research SAKK 20/88

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003370.PUB2

7 January 2021

CGS 16949A, a new aromatase inhibitor in the treatment of breast cancer--a phase I study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003370.PUB2

7 January 2021

Second-line hormonotherapy for breast cancer. Uselessness of first-line continuation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003370.PUB2

7 January 2021

Randomized trial of tamoxifen versus aminoglutethimide and versus combined tamoxifen and aminoglutethimide in advanced postmenopausal breast cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003370.PUB2

7 January 2021

A randomised comparison of oestrogen suppression with anastrozole and formestane in postmenopausal patients with advanced breast cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003370.PUB2

7 January 2021

Randomized trial of tamoxifen alone or combined with aminoglutethimide and hydrocortisone in women with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003370.PUB2

7 January 2021

Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003370.PUB2

7 January 2021

Randomized phase III trial comparing the new potent and selective third-generation aromatase inhibitor vorozole with megestrol acetate in postmenopausal advanced breast cancer patients. North American Vorozole Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003370.PUB2

7 January 2021

Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003370.PUB2

7 January 2021

Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003370.PUB2

7 January 2021